As was showed in Figure 13 and Table 2, Nutlin-3a (−) had a significant increased resistance in TP53 mutation (P = 2.12e-06) of BLCA patients and the IC50 of Nutlin-3a (−) was significantly increased in TP53 mutation group (P < 0.001). Here, TP53 is linked to bladder transitional cell carcinoma.